Anti-IL-18BP antibodies
Inventors
Horlick, Robert A. • Jun, Helen Toni • WILLEN, Magdalena S. • CHIDESTER, Christine M. • BARRETT, Mark G. • King, David J. • WITHERDEN, Deborah A.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12365737-B2
Publication Date
2025-07-22
Expiration Date
Abstract
Provided are antibodies that bind to interleukin-18 binding protein (IL-18BP) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers and other diseases.
Core Innovation
The invention relates to anti-interleukin-18 binding protein (IL-18BP) antibodies and related compositions in which the antibody interferes with the binding of IL-18 to IL-18BP. The disclosed antibodies are defined by heavy chain variable region (V_H) and light chain variable region (V_L) complementarity determining region (CDR) sequences, including exact amino acid sequences and multiple SEQ ID NO-defined CDR sets.
The antibody interferes with IL-18 binding to IL-18BP, including through binding that disrupts IL-18/IL-18BP interactions. The description includes antibody antagonist or competitor function for IL-18BP and binding specificity across IL-18BP isoforms and orthologs, including human, cynomolgus, and mouse IL-18BP, as well as binding to free IL-18BP and preformed IL-18/IL-18BP complexes.
The disclosed antibodies and compositions are associated with therapeutic contexts including cancers and infectious diseases. The patent also includes pharmaceutical compositions and patient-care kit concepts in which the IL-18BP-specific antibody is formulated with pharmaceutically acceptable carriers.
Claims Coverage
The partial claims provided include two independent claims. Both are directed to an antibody specific for IL-18BP that interferes with the binding of IL-18 to IL-18BP, with the inventive scope defined by constrained heavy-chain and light-chain CDR sequence content.
Interference with IL-18 binding to IL-18BP using defined V_H and V_L CDR sequences
An antibody specific for interleukin-18 binding protein (IL-18BP), wherein the antibody interferes with the binding of IL-18 to IL-18BP, and wherein the antibody comprises a heavy chain variable region (V_H) comprising complementarity determining region V_H CDR1, V_H CDR2, and V_H CDR3 sequences, and a light chain variable region (V_L) comprising complementarity determining region V_L CDR1, V_L CDR2, and V_L CDR3 sequences, with exact CDR amino acid sequences and a limited substitution option for V_L CDR3.
Interference with IL-18 binding to IL-18BP using multiple SEQ ID-defined V_H and V_L CDR sets
An antibody specific for interleukin-18 binding protein (IL-18BP), wherein the antibody interferes with the binding of IL-18 to IL-18BP, and wherein the antibody comprises a heavy chain variable region (V_H) and a light chain variable region (V_L) defined by multiple alternative SEQ ID NO sets for the corresponding CDR sequences.
Across the two independent claims, the claim coverage is directed to IL-18BP-specific antibodies that interfere with IL-18 binding to IL-18BP. The distinguishing inventive matter is the definition of antibody specificity by constrained CDR sequence content, implemented as either exact CDR amino acid sequences with a limited substitution option or as membership in multiple SEQ ID-defined CDR sequence sets.
Stated Advantages
Increase IL-18 signaling outputs, including IFN-γ, CXCL10, and TNFα.
Documented Applications
Treating cancers, including MDS, using anti-IL-18BP antibodies.
Treating infectious diseases using anti-IL-18BP antibodies.
Disease application areas are described broadly, with notable emphasis on cancers/tumor indications.
Interested in licensing this patent?